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Abstract
Background: A significant proportion of breast cancer patients face failure of endocrine therapy due to the acquisition of
endocrine resistance. We have explored mechanisms involved in such disease progression by using a mouse breast cancer
model that is induced by medroxyprogesterone acetate (MPA). These tumors transit through different stages of hormone
sensitivity. However, when cells from tumor variants were seeded on plastic, all were stimulated by progestins and inhibited
by antiprogestins such as RU486. Furthermore, cells from a RU486-resistant tumor variant recovered antiprogestin
sensitivity.
Hypothesis: A three-dimensional (3D) culture system, by maintaining differential cellular organization that is typical of each
tumor variant, may allow for the maintenance of particular hormone responses and thus be appropriate for the study of the
effects of specific inhibitors of signaling pathways associated with disease progression.
Method: We compared the behavior of tumors growing in vivo and cancer cells ex vivo (in 3D Matrigel). In this system, we
evaluated the effects of kinase inhibitors and hormone antagonists on tumor growth.
Principal Findings: LY294002, a PI3K/AKT pathway inhibitor, decreased both tumor growth in vivo and cell survival in
Matrigel in MPA-independent tumors with higher AKT activity. Induction of cell death by anti-hormones such as ICI182780
and ZK230211 was more effective in MPA-dependent tumors with lower AKT activity. Inhibition of MEK with PD98059 did
not affect tumor growth in any tested variant. Finally, while Matrigel reproduced differential responsiveness of MPA-
dependent and -independent breast cancer cells, it was not sufficient to preserve antiprogestin resistance of RU486-
resistant tumors.
Conclusion: We demonstrated that the PI3K/AKT pathway is relevant for MPA-independent tumor growth. Three-
dimensional cultures were useful to test the effects of kinase inhibitors on breast cancer growth and highlight the need for
in vivo models to validate experimental tools used for selective therapeutic targeting.
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Introduction
Signaling pathways in breast tumor progression
About two-thirds of breast cancers express a functional estrogen
receptor (ER) and are initially dependent on 17b-estradiol for
growth and survival. However, eventually some of these cancers
progress to hormone independence [1]. Endocrine therapies,
which inhibit ER signaling, are the most common and effective
treatments for ERa-positive breast cancer. These include the
selective ER down-regulators tamoxifen and fulvestrant
(ICI182780) [2] and the aromatase inhibitors [3]. However, the
use of these agents is limited by the frequent development of
resistance after prolonged treatment. Another steroid receptor that
has gained special attention in the last years of research on breast
cancer is the progesterone receptor (PR). Endocrine therapies
using mifepristone (RU486) [4,5] or ZK230211 [6,7] that block
the function of PR have not yet been extended into patients and
more preclinical studies are required to understand their
mechanisms of action.
Several studies have focused on the compensatory cross-talk
between steroid receptors and various signaling pathways activated
by tyrosine kinases associated with growth factor receptors [1,8,9].
These studies have shown that such cross-talk may account for the
autonomous growth and for the progression to decreased
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particular, activation of the phosphatidylinositol-3-OH kinase
(PI3K)/Protein kinase B (AKT/PKB) survival pathway has been
implicated in the progression of endocrine-resistant tumors [10–
12] and has been associated with poor prognosis [13,14]. The
same studies suggest that AKT is a potential target for the
development of new antitumor therapies. Another kinase that is
involved in the progression of hormone resistance is mitogen-
activated protein kinase (MAPK)/extracellular signal-regulated
kinase (ERK) [15], and specific inhibitors of ERK kinase (MEK)
have been developed that efficiently inhibit the oncogenic RAS-
MEK-ERK pathway.
During the translation of basic science, it is still inevitable that
some of the treatments do not work, or after a variable period of
time under treatment, refractory mechanisms arise and tumor
relapse occurs [1,15]. One reason for the relapse might stem, as
mentioned above, from alterations in the activity of signaling
pathways in a given tumor. Another reason is the variability in the
behavior among different tumor variants, which results from the
intrinsic heterogeneity of tumor cells (genetic and epigenetic) [16]
and the heterogeneous environment in which the cells reside inside
the tumor [17–19]. Hence, cancer therapy agents that induce
apoptosis can be effective for some kinds of tumors but not for
others. For these reasons, understanding the sources of this
variability might have a significant therapeutic impact.
Tumor microenvironment
All components of the mammary gland, in addition to the
luminal and/or tumor epithelial cells, are instrumental in
maintaining organ integrity and promoting and, at times, even
initiating breast cancer development [18,20]. Consequently,
important signals are lost when cells are cultured ex vivo on two-
dimensional (2D) plastic substrata. Many of these crucial
microenvironmental cues may be restored by generating three-
dimensional (3D) cultures that use laminin-rich extracellular
matrix (commercial Matrigel). This model provides an excellent
system to study tissue organization, epithelial morphogenesis
[21,22], and breast carcinogenesis [23–25] in a more physiological
context.
Paradigmatic studies in Dr. Bissell’s laboratory have shown that
it is possible to revert the malignant phenotype by targeting
environmental factors [24,26,27] and by correcting alterations in
signal transduction pathways [28,29], both in vivo and in culture,
without altering the genetic lesions of the tumor, summarized in
[30,31].
Mouse mammary tumor model
The number of relevant and well-characterized animal models
for studying breast cancer is small [32–34], and this represents a
limitation for research in the field. With the aim of developing new
experimental systems for in vivo studies of hormone-dependent and
-independent tumor growth, progression and invasion, we have
made use of a murine experimental model of breast cancer that is
induced by the progesterone analog medroxyprogesterone acetate
(MPA) [35,36]. The original tumor variant requires the admin-
istration of MPA to grow (hormone-dependent, HD). Spontane-
ously, a group of tumors begin to grow in the absence of MPA
(hormone-independent, HI) [37]. These two tumor variants retain
a ductal phenotype and maintain functional ER and PR [37,38]
reviewed in [39]. However, a member of HI tumors, C4-HI,
display a more differentiated pattern [7], compared to a member
of HD tumors, C4-HD [40]. Therefore, as is often found in the
clinic, loss of hormone dependence in this model was not due to
the loss of expression of steroid receptors. Moreover, a recent
study reported that carcinoma-associated fibroblasts derived from
C4-HI tumors produce higher levels of fibroblast growth factor-2
(FGF-2) than fibroblasts derived from C4-HD tumors [41].
Whereas C4-HD and C4-HI tumors regress after treatment with
RU486 or tamoxifen [40,42], another tumor variant with acquired
resistance to antiprogestin therapy, C4-HIR, was obtained by
prolonged selective pressure of C4-HI tumors with RU486. This
variant exhibits greater activation of ERK and metastatic potential
[7].
Thus, the MPA model progresses through different stages of
hormone responsiveness [7,40,42], and it is especially useful for
studies of hormone receptor function, protein kinase involvement
and the role of stromal elements in tumor progression. Together,
the evidence suggests that changes in the signaling pathways
involving steroid receptor regulation, rather than loss of
expression, might impact tumor susceptibility to treatment.
However, the signaling pathways involved in the different tumor
phenotypes are still unidentified in the MPA model.
In this study, the 3D Matrigel culture system, by preserving the
physiologically relevant microenvironment that more closely
mimics tumor architecture, causes cancer cells to function as they
do in vivo. In this system, we show that AKT activation is involved
in ERa expression and in the progression of MPA-induced
mammary tumors to a hormone-independent phenotype. Fur-
thermore, we proved our hypothesis that the activation of
particular signaling pathways depends on the interaction of
epithelial tumor cells with their microenvironment. However,
the 3D Matrigel system is still insufficient to reproduce the
responsiveness of acquired tumor resistance. The ultimate goal is
to use this model to develop a preclinical assay to predict cancer
sensitivity to antitumor agents in order to prevent or delay the
surge of hormone-independent and endocrine-resistant tumor
variants.
Results
PI3K/AKT signaling pathway regulates growth of C4-HI
but not C4-HD tumors
In order to understand the mechanisms involved in the
transition from hormone-dependent to hormone-independent
mammary tumors, we have focused our study on the role of
PI3K and of MEK induced signaling, as deduced by assessment of
AKT and ERK1/2 phosphorylation after exposure to PI3K and
MEK inhibitors, respectively.
Analysis by western blotting revealed that, in comparison with
C4-HD tumors, C4-HI tumors exhibit higher activation of both
AKT and ERK1/2 (p,0.05; Figure 1A). Kinase activation level
was quantified as the ratio of phosphorylated Ser473 AKT (p-
AKT) to total AKT, and the ratio of phosphorylated ERK1/2 (p-
ERK1/2) to total ERK1/2, respectively (Figure 1A, bar graphs).
Immunohistochemistry analysis showed a more intense signal for
p-AKT in C4-HI tumors (Figure 1B), confirming western blots
results.
The involvement of the two signaling pathways in mammary
tumor growth was evaluated using specific inhibitors: PD98059, an
inhibitor of MEK1, and LY294002, an inhibitor of PI3K. Briefly,
3.6 mg/kg PD98059, 4 mg/kg LY294002 or 100 ml of saline
solution (control) were administrated i.p. to animals carrying C4-
HD or C4-HI tumors as indicated in Materials and Methods.
Neither of the inhibitors could interfere with C4-HD tumor
growth (Figure 1 C left). In contrast, a significant decrease in
tumor growth was observed in C4-HI tumors treated with
LY294002 (p,0.01; Figure 1C right), indicating that the activity
of the PI3K/AKT pathway is necessary for C4-HI tumors to
3D Assay and Tumor Sensitivity
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10786Figure 1. The PI3K/AKT pathway regulates growth in C4-HI but not in C4-HD tumors. C4-HD tumors were transplanted into BALB/c
females carrying a MPA depot while C4-HI tumors were transplanted in the absence of MPA. When tumors reached a 150 mm
2 of size, they were
removed and processed as described in Materials and Methods for western blot or immunohistochemistry. A. Left. Western blots of protein extracts
from C4-HD and C4-HI tumors using specific antibodies against phosphorylated Ser473 AKT (p-AKT), total AKT, phosphorylated ERK1/2 (p-ERK1/2),
total ERK1/2 and b-actin (loading control). Three representative samples of a total of six of each tumor type are shown. Right. Quantification of AKT
activation (p-AKT relative to total AKT levels) and ERK activation (p-ERK relative to total ERK levels). n=6 for each tumor type; *: p,0.05 C4-HI vs. C4-
HD. B. Immunohistochemistry of slices of paraffin embedded C4-HD or C4-HI tumors using antibodies against phosphorylated Ser473 AKT, showing a
higher number of p-AKT-positive cells in C4-HI than in C4-HD tumors. Brown corresponds to the antibody signal and blue marks nuclei stained with
hematoxylin. Scale bar: 60 mm. C. 3.6 mg/kg PD98059 (MEK inhibitor), 4 mg/kg LY294002 (PI3K inhibitor) or 100 ml of saline solution (c, control) were
administrated i.p. every other day for 12 days to animals carrying C4-HD or C4-HI tumors. Length and width of mammary tumors (mm
2) were
measured every 2 days. Treatments with the inhibitors started once the tumors reached a size of approximately 30 mm
2. Treatment with LY294002
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presence of MPA (not shown), indicating that the differential effect
of LY294002 in the two tumor variants was not due to the
influence of the progesterone analog.
It is important to point out that the growth rate of C4-HI
tumors growing with (not shown) or without MPA (Figure 1C) was
higher than the rate of C4-HD tumors growing with MPA. This is
not surprising since we have already reported that the growth rate
depends on the number of passages used in each tumor line, and
C4-HI tumors include more passages than the original C4-HD
tumors [39].
Even though the activation of ERK1/2 was also increased in
C4-HI tumors as compared to C4-HD tumors (Figure 1A), the
role of the RAS-RAF-MEK-ERK1/2 pathway in tumor growth
does not seem to be pivotal since PD98059 treatment did not
interfere with either C4-HD or C4-HI tumor growth (Figure 1C).
After 12 days of treatment with the inhibitors, animals were
euthanized and the tumor samples were excised for protein
analysis by western blots. We found a significant reduction
(p,0.05) in the levels of p-AKT and p-ERK1/2 in both tumor
types as a result of treatment with LY294002 and PD98059,
respectively (Figure 1D). This result confirms the effectiveness of
these drugs to inhibit their molecular targets. Histological analysis
of the tissues shows, as expected, an increase (p,0.01) in the
percentage of apoptotic cells in C4-HI tumors treated with
LY294002 (Figure 1E). Consistent with the observation that the
treatment with PD98059 did not reduce the growth rate of either
tumor (Figure 1C) we did not see a significant increase in the
apoptosis index in tumors treated with PD98059 by the end of the
experiment (Figure 1E).
Finally, we observed that C4-HI tumors, independently of MPA
supply, display ductal-like structures (indicated by the black arrows
in Figure 1F). These results are consistent with previous studies
[7,40,42] that show a more glandular-like differentiation pattern in
C4-HI than C4-HD tumors. Moreover, treatment with LY294002
causes an increase in this differentiation pattern only in C4-HI
tumors (Figure 1F).
Cancer cells isolated from C4-HD and C4-HI tumors lose
differential sensitivity to the inhibition of the PI3K/AKT
pathway
In order to study the mechanisms that lead to the differential
activation of AKT in C4-HI and C4-HD tumors, we isolated
primary epithelial cells from the tumors and cultured them on
plastic tissue culture plates. Under this two-dimensional (2D)
condition, both C4-HD and C4-HI epithelial cells grow as clusters
that adhere to the plastic (Figure 2A). In contrast to the results
obtained with tumors growing in vivo, western blot analysis of
epithelial cells isolated from C4-HD or C4-HI tumors that were
placed on plastic for 96 hours show similar levels of p-AKT and p-
ERK1/2 (Figure 2B). Furthermore, analysis of cell proliferation by
3H-thymidine uptake revealed that both cell types have a similar
responsiveness to MPA or growth factors such as FGF-2 [41], and
both display similar sensitivity to the inhibitors PD98059 and
LY294002, as shown here (Figure 2C). In both cell types,
inhibition of PI3K/AKT and MEK/ERK1/2 signaling interfered
with the proliferative effect of 0.01 mM MPA (Figure 2C),
suggesting that both pathways are involved in MPA-induced
proliferation. Curiously, even though C4-HI tumor cells are MPA-
independent in vivo, they are MPA-responsive in vitro.
As expected, after 10 mM PD98059 and LY294002 treatments,
there was a reduction in the levels of p-ERK1/2 (p,0.01) and p-
AKT (p,0.05), respectively (Figure 2D) confirming that both
inhibitors were able to exert their specific effects. In addition,
LY294002 caused a slight decrease in AKT protein levels
(Figure 2D). Finally, we also observed a reduction in the levels
of p-ERK1/2 in the presence of LY294002 suggesting a functional
connection between the PI3K/AKT and MEK/ERK1/2
pathways.
The striking difference between the behavior of tumor cells in
vivo vs. in vitro indicated that, not only hormone regulation, but also
the activation of PI3K/AKT and MEK/ERK1/2 signaling
pathways, are strongly influenced by the tumor microenvironment
and/or host factors. Consistent with this hypothesis are our
previous findings demonstrating that C4-HI-derived cancer
associated fibroblasts are able to induce PR activation and cell
proliferation of epithelial cells more efficiently than C4-HD-
derived cancer associated fibroblasts [41]. This discovery indicates
that stromal signals are critical in the maintenance of hormone-
dependency and can also affect the activation of protein kinases in
breast tumors. Naturally, these stromal signals are lost when
cancer cells are isolated from the tissue and cultured on tissue
culture plastic.
Differential activation of PI3K/AKT pathway can be
maintained in culture when isolated cancer cells preserve
their tissue organization
Monolayers of C4-HD and C4-HI primary tumor cells placed
on tissue culture plastic lack 3D tissue organization, leading to a
loss of normal cell to cell interactions. Under these conditions,
immunofluorescence to reveal integrin a6, a protein belonging to a
class of extracellular matrix receptors that are normally localized
to the basal membrane of polarized cells, showed a disorganized
distribution of this protein in epithelial cells derived from both
types of tumors, with no polarization pattern (Figure 3A).
In an effort to find an in vitro culture system that reproduces the
differential phenotype and behavior of C4-HD and C4-HI tumor
cells that we observed in vivo, we tested the ‘on-top’ assay, in which
cells are cultured on top of a thin laminin-rich gel (Matrigel). In
these conditions, cells remained as clusters and maintained a 3D
structure (Figure 3B). Forty-eight hours after seeding on top of the
Matrigel, primary cells derived from C4-HD and C4-HI tumors
became enclosed by a rigid structure, and integrin a6 showed
basal cell membrane localization by immunofluorescence
(Figure 3B). This result suggests that basement membrane
components are appropriately deposited. Within this enclosure,
most primary C4-HI tumor cells formed polarized and hollow
structures, which resemble the lumen present in ductal-like
structures found in normal mouse mammary epithelial organoids
placed on Matrigel (Figure 3B right). Furthermore, C4-HI cells
causes C4-HI tumors to have a decreased growth rate. n=6 for each group; **: p,0.01 vs. control. D. Left. At the end of 12 days of treatment, tumors
were removed to evaluate by western blot the inhibitory effect of PD98059 and LY294002 on p-ERK1/2 and p-AKT, respectively. Two representative
samples of a total of six are shown in the gel (left). Right. Quantification of AKT and ERK activation as in A. n=6 for each group; a,b: p,0.01 C4-HI vs.
C4-HD; *:p,0.05 vs. control. E. Quantification of the percentage of apoptosis at the end of treatment. Data corresponds to the mean6SEM
percentage of apoptotic cells in ten high-power fields corresponding to six independent experiments. Apoptosis is higher in C4-HI tumors treated
with LY294002. **: p,0.01 vs. control. F. C4-HI tumors are more differentiated than C4-HD tumors. After 12 days of treatment with LY294002, there is
an increase in the number of ductal-like structures only in the C4-HI tumors, as indicated by the black arrows. Scale bar: 30 mm.
doi:10.1371/journal.pone.0010786.g001
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PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10786Figure 2. Differential sensitivity to PI3K/AKT pathway regulation is lost in isolated cancer cells. A. Phase contrast microscopy of primary
cultures isolated from C4-HD and C4-HI tumors showing flattened monolayers on tissue culture plastic. Scale bar: 30 mm. B. Top. Western blots
showing p-AKT, total AKT, p-ERK1/2, ERK1/2 and b-actin in protein extracts from primary cells cultured for 96 hrs. Three representative samples of a
total of six are shown in the gel. Bottom. Quantification of p-AKT/total AKT and p-ERK/total ERK levels, n=6 for each cell type. C. Proliferation assay
(
3H-thymidine incorporation) in primary C4-HD (left) or C4-HI (right) cells incubated during the last 48 hrs with 0.01 mM MPA and 5, 10 and 20 mM
PD98059 or LY294002. For the combined treatment, the inhibitor was used at a dose of 10 mM.
3H-thymidine was added in the last 18 hrs before
harvesting the cells. MPA has a stimulatory effect while PD98059 and LY294002 have an inhibitory effect on MPA-treated and untreated cells. n=8 for
each treatment. ***:p,0.001; **:p,0.01; *: p,0.05 vs. control (untreated cells); different letters indicate significant differences between treatments in
the presence of MPA with p,0.01. A representative experiment of a total of three is shown here. D. Left. Western blots showing that phosphorylation
levels of AKT and ERK1/2 decrease in primary C4-HI cultures incubated for 48 hrs with 10 mM of specific inhibitors. b-actin levels in the blot serve as a
loading control. Two representative samples of a total of six are shown (left). Right. Quantification of p-AKT/total AKT and p-ERK/total ERK levels. n=6
for each group; *p,0.05; **p,0.01 vs. control.
doi:10.1371/journal.pone.0010786.g002
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lateroapical localization of ZO-1 (Figure 3B), a central regulator of
tight junction formation. In contrast, most C4-HD tumor cells
placed on Matrigel form clusters that are much less polarized, with
lower levels of integrin a6, MUC-1 and ZO-1 signal (Figure 3B),
and hollow tissue structures are rarely seen.
Moreover, this culture system is reminiscent of the differences in
tissue organization observed between C4-HD and C4-HI tumor
variants, where C4-HI tumors growing in the absence or presence
of MPA show a high degree of differentiation with a ductal-like
organization of epithelial cells, while C4-HD tumors are much less
differentiated (Figure 1F).
Under these culture conditions, western blots of C4-HI cells
showed higher levels (p,0.01) of p-AKT and p-ERK1/2 as
compared to C4-HD cells (Figure 3C), resembling the in vivo results
(Figure 1A,B,D). In conclusion, in vitro 3D results reproduced in vivo
results and revealed that the differences between tumor variants in
the activation level of protein kinases could be determined by a
particular cell context.
Differential sensitivity to the PI3K/AKT pathway between
tumor cell types is restored under conditions that allow
correct tissue organization
We then explored the sensitivity of C4-HD and C4-HI cells
growing for 96 hrs on Matrigel to PD98059 and LY294002
treatment. Analysis of phase contrast microscopy images revealed
critical differences between the two cell types to kinase inhibitor
treatment. Similar to what we found in vivo (Figure 1E), the PI3K
inhibitor reduced cell survival (determined by cluster size) in C4-
HI cells significantly more than in C4-HD cells (Figure 4).
Furthermore, a small effect was observed using the MEK inhibitor
in C4-HI cells. The simultaneous treatment with both inhibitors
was remarkably effective both on C4-HD and C4-HI cells in
Figure 3. Differential activation of the PI3K/AKT pathway in tumor cells is cell context dependent. Primary cancer cells in 3D cultures
‘‘on top’’ of Matrigel reproduced the architecture typical of the tumors, as well as the differential pattern of protein kinase activation between cells
types. A. C4-HD and C4-HI primary cells isolated from the tumor and placed on tissue culture plastic for 48 hrs show diffuse and irregular deposition
of integrin a6 as assayed by immunofluorescence under confocal microscopy. B. Phase contrast microscopy (top) of primary cells placed on top of a
thin layer of Matrigel. After 48 hrs, the cells show differences in organization among the three cell types. Confocal images from immunofluorescence
studies (bottom) reveal that C4-HI cells (right) form organized clusters with an appropriate continuous basal localization of integrin a6, resembling
normal mammary organoids in culture. C4-HI cells exhibit apical localization of MUC-1 on the surface of the cell membrane, lateral localization of tight
junction protein ZO-1 and even the presence of a central lumen in some of the clusters. C4-HD cells (left) remain as disorganized clusters, with no
clear distribution of any polarity marker tested and no central lumen. Polarity markers were stained green with specific antibodies for
immunofluorescence; nuclei were stained red with propidium iodide. Representative clusters of each condition are shown here. Scale bar: 30 mm. C.
Top. Western blot of protein extracts obtained from primary cultures grown on Matrigel showing that differences on p-AKT and p-ERK1/2 levels
between C4-HD and C4-HI tumors is preserved when isolated cells are placed on 3D culture system. b-actin levels in the blot serve as a loading
control. Three representative samples of a total of six are shown. Bottom. Quantification of p-AKT/total AKT and p-ERK/total ERK levels. n=6 for each
cell type; **p,0.01 C4-HI vs. C4-HD.
doi:10.1371/journal.pone.0010786.g003
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with 10 mM LY294002 increased central lumen formation
(indicated with red arrows in Figure 4) in C4-HI clusters. To
evaluate if there is a selective effect of LY294002 in inducing cell
death in C4-HI cells, we used the acridine orange/ethidium
bromide (AO/EB) dye incorporation assay. By this technique,
apoptotic cells are visualized by their red fluorescence whereas
living cells fluoresce green. An analysis of phase contrast
Figure 4. Higher sensitivity of C4-HI tumors to inhibition of PI3K/AKT pathway is restored in 3D Matrigel. The 3D Matrigel culture
system reproduces the in vivo differential sensitivity of primary cancer cells to PI3K and MEK inhibitors. Phase contrast microscopy showing the
progression of C4-HD (top) and C4-HI (bottom) cultures in the presence of 10 mM PD98059, LY294002, or vehicle as control. Day 0 referred to the day
of the isolation from the tumors. Primary cultures were maintained for 96 hrs on Matrigel, and the inhibitors were added into the culture medium for
the last 48 hrs. During that time, under control conditions the clusters became bigger, due to proliferation and superposition of neighboring clusters.
PD98059 causes a small reduction in the size of C4-HI clusters, but the effect of LY294002 is more dramatic on C4-HI than C4-HD cells. A higher
number of structures with central lumen (indicated with red arrows) were noticeable in LY294002-treated C4-HI cells. Simultaneous treatment with
the two inhibitors equally reduced the size of C4-HD and C4-HI clusters. Scale bar: 30 mm. The same progression was observed in three independent
experiments.
doi:10.1371/journal.pone.0010786.g004
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microscope of AO/EB staining demonstrated that C4-HD and
C4-HI cell clusters were differentially sensitive to protein kinase
inhibitors. After 48 hrs of LY294002 treatment, a significant
increase (p,0.01) in the number of apoptotic C4-HI but not C4-
HD cells was observed. In contrast, PD98059 did not significantly
increase the percentage of C4-HI or C4-HD apoptotic cells
(Figure 5A). Taken together, these data suggest that C4-HD
clusters do not have lumen because of their failure to undergo
cavitations via the apoptosis of centrally localized cells (Figure 5A).
To determine the mechanisms by which AKT selectively
regulates the survival of C4-HI cells, we measured the levels of pro
and anti-apoptotic molecules by immunofluorescence. We found
that after treating the cells for 48 hrs with LY294002, there was a
decrease in the anti-apoptotic protein Bcl-XL, and an increase
both in the pro-apoptotic molecule BAX and activated caspase-9
(Figure 5B).
In conclusion, our results indicate that a major difference
between C4-HD and C4-HI cells is the relevant role of the PI3K/
AKT pathway in the regulation of cell survival in C4-HI cells and
that the activity of this pathway requires an appropriate 3D cell
context.
The activation of AKT is involved in the regulation of ERa
levels
In order to find other mechanisms responsible for the difference
in growth between C4-HD and C4-HI tumors, we investigated
wether the PI3K/AKT and ERK1/2 pathways regulated the
levels of ERa. Inhibition of either pathway significantly (p,0.01)
reduced the expression levels of ERa in C4-HI tumors but not in
C4-HD tumors as assessed by western blot (Figure 6A). This result,
together with our finding that inhibition of p-ERK by PD98059
did not reduce tumor growth rate (Figure 1C), suggest that at least
in C4-HI cells, cell proliferation and cell survival are not
determined exclusively by ERa levels.
We cultured pure C4-HD and C4-HI primary cells on plastic
and then treated them with PD98059 and LY294002. In contrast
to the above results, both cell types responded similarly to the
inhibitors with a decrease in ERa expression (not shown).
Therefore, we decided to grow the cells on Matrigel. When tumor
cells were placed on Matrigel, we observed that C4-HI cells
exhibited a higher sensitivity, in terms of ERa expression levels, to
10 mM LY294002 and PD98059, than C4-HD cells. ERa levels
decreased in C4-HI cells treated with any of the inhibitors for
48 hrs (p,0.01), while ERa levels remained unaltered in C4-HD
cells, as determined by western blot (Figure 6B). Immunofluores-
cence analysis confirmed the results observed by western blot,
showing decreased signal for ERa after C4-HI, but not C4-HD
cells growing on Matrigel, were treated with the kinase inhibitors
(Figure 6C).
Finally, in order to demonstrate that there is a direct
relationship between AKT activation and ERa regulation, we
transfected Scp2, a non-tumorigenic mouse mammary cell line,
with a constitutively active form of AKT1, myristoylated AKT1-
D4-129 (Scp2Akt). Western blot analysis of these cells revealed a
band of 59 kDa corresponding to phospho-Ser473 wild type AKT
and a smaller band of 45 kDa corresponding to myristoylated
phospho-Ser473 AKT1 (Figure 6D). In Scp2Akt cells ERa
expression is increased (p,0.05) in comparison to untransfected
Scp2 cells and Scp2 cells transfected with the control vector,
Scp2vc (Figure 6D), confirming that ERa expression can be
directly regulated by AKT. As expected, 2 and 5 mM LY294002
reduced p-AKT and ERa (p,0.05) levels in Scp2 and Scp2vc
cells. Furthermore, the inhibitory effect of LY294002 was smaller
in Scp2Akt cells, since constitutively active AKT does not require
the activity of PI3K to move to the plasma membrane. This result
confirms that the regulatory effect of PI3K occurs through AKT.
It is important to mention that the antibody used to detect total
AKT recognizes amino acids 71–184 overlapping with the
deletion fragment in the myristoylated AKT1, and for that reason
the only band observed corresponds to the endogenous, wild type
AKT (Figure 6D). E-cadherin protein was used as a loading
control for Scp2 cells as previously described [43].
These results indicate that protein kinase signaling can regulate
tumor growth by regulating steroid receptor availability in cancer
cells, which could shape the response of the tumor to endocrine
therapy.
Differential sensitivity to steroid receptor inhibitors by
C4-HD tumor cells
We then used the Matrigel culture system to compare the effects
of other inhibitors in this model that could be differentially
effective in inhibiting C4-HD tumor growth. We tried two well-
known steroid receptor inhibitors that are already in preclinical
use and are known to be effective in MPA-induced mammary
tumors, such as ICI182780, an ER antagonist, and ZK230211, a
PR antagonist. Using the AO/EB dye incorporation assay, we
found a higher number of apoptotic cells (visualized by red
fluorescence) after 48 hrs of treatment with 1 mM ICI182780 or
0.01 mM ZK230211 only in C4-HD tumor cells (p,0.001)
(Figure 7, photographs and bar graphs). Moreover, the percentage
of apoptotic C4-HI cells did not significantly increase in the
presence of any of the steroid receptor inhibitors tested (Figure 7,
right bar graph).
These results support the idea that a culture system using
Matrigel efficiently maintains in vitro the differential cellular
responses observed in vivo to specific inhibitors that target signaling
pathways at different levels. Then, this culture system could be a
tool used to find selective antitumor agents against individual
tumor types.
Reconstitution of tissue organization in culture is not
sufficient to prevent loss of endocrine resistance of
isolated C4-HIR tumor cells
Finally, we evaluated whether endocrine resistance of C4-HIR
tumors can be reproduced in culture using Matrigel as a
substratum. As previously reported [7] and reproduced here
(Figure 8A), C4-HI tumors regress after antiprogestin treatment
(ZK230211 or RU486). This is in contrast to C4-HIR tumors,
which continue growing following the same treatment. However,
when primary cells were isolated from each tumor and placed on
plastic, both cell types were sensitive to RU486 (unpublished data).
Furthermore, this loss of endocrine resistance of C4-HIR tumor
cells could not be prevented by culturing the cells on Matrigel.
After 48 hrs of 0.01 mM RU486 treatment, both C4-HI and C4-
HIR tumor cells were equally sensitive to the antiprogestin,
showing similar increase (p,0.001) in the percentages of apoptotic
cells (visualized by red fluorescence) when assayed by AO/EB dye
uptake (Figure 8B). Under the same conditions, it was noticeable
that treatment with 0.01 mM MPA for 48 hrs did not significantly
affect basal cell death in both C4-HI and C4-HIR cultures
(Figure 8B). It is important to mention that C4-HIR cells remained
more disorganized than C4-HI cells on Matrigel (Figure 8B,
photographs).
These results indicate that all of the phenomena involved in
differential tumor sensitivity to antitumor agents can not be
reproduced using Matrigel as a culture system. In the case of
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10786Figure 5. Cell death induced by LY294002 in C4-HI cancer cells involves intrinsic BAX/mitochondrial/caspase-9 apoptotic pathway.
The 3D Matrigel culture system of primary C4-HI cancer cells reproduces the increased pro-apoptotic effect of the PI3K inhibitor observed in vivo. A.
Top. Phase contrast microscopy showing a representative C4-HD (left) and C4-HI (right) cell cluster cultured for 96 hrs on Matrigel and treated for the
last 48 hrs with 10 mM PD98059, LY294002, or vehicle as control. Confocal images from a fluorescence microscope of acridine orange/ethidium
bromide (AO/EB) staining was used to discriminate live from apoptotic cells. AO fluoresces green in live cells and EB fluoresces orange/red when
intercalated with DNA in dead cells. Most C4-HI cell clusters on Matrigel exhibit a central lumen. In contrast, no C4-HD cell clusters possess a central
lumen. A higher number of apoptotic cells in and around the central lumen of LY294002-treated C4-HI cells was also noted. Scale bar: 30 mm. Bottom.
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be required to maintain this tumor phenotype.
Discussion
In this work, we have combined the advantages of using an
experimental mouse model that spans the different stages of
endocrine responsiveness and mimics critical events in the most
frequent type of breast cancer in women [39] with the 3D Matrigel
culture system that mimics tissue architecture in vitro. Under these
conditions, we were able to reproduce in vitro many of the in vivo
behaviors of C4-HD and C4-HI tumors. The ability to do
experiments in culture allowed us dissecting some of the
mechanisms involved in the acquisition of hormone independence.
We found that AKT is highly active in C4-HI but not in C4-HD
tumors and that it regulates C4-HI tumor growth (Figure 1) and
cell survival (Figure 5). In contrast, ERK1/2, which is also highly
active in C4-HI tumors, is not relevant for tumor growth or cell
survival. These results suggest that upregulation of the PI3K/AKT
pathway might be a key event in the progression to hormone
independence. LY294002 has already been used in preclinical
studies [44,45] and, consisting with the results shown here, its has
been shown that its effect in reducing cell survival and tumor
growth in mouse thyroid cancers is through a decrease in the
phosphorylation of BAD and an increase in proapoptotic caspase 3
[45]. On the other hand, C4-HD tumor cells are more sensitive to
steroid receptor antagonists such as ICI182780 and ZK230211
(Figure 7), indicating that in the original tumor variant steroid
receptor signaling is prevalent in driving tumor growth and cell
survival. Assuming that the signaling pathways that participate in
tumor growth and cell survival of each tumor type are indicative of
the mechanisms involved in tumor progression, we hypothesize
that C4-HI tumors shifted from steroid receptor to the PI3K/
AKT signaling pathway dependency. However, our in vitro results
have shown that only in a 3D Matrigel culture this differential
tumor dependency is preserved.
In the future, the 3D Matrigel system will allow us to identify
specific regulatory elements missregulated in C4-HI tumors that
lead to a hyperactive PI3K/AKT pathway, which might be
related to the acquisition of hormone independence. Elucidation
of these mechanisms might lead to the development of therapies
for preventing and treating hormone-independent breast cancers.
Then, an in vitro system that preserves in vivo differential tumor
phenotype, constitutes a prospective tool in finding selective
antitumor agents against individual tumor types.
The fact that the dependency of C4-HI tumors on AKT is lost
in classic 2D cultures but it is maintained in 3D cultures of nearly
pure tumor epithelial cells (compare Figures 2 and 5) indicates that
acini-like tissue structure, rather than factors originating in stromal
cells, plays a key role on such dependency. Similarly, Zhang and
collaborators [46] have shown that estrogen-induced apoptosis of
the human ductal breast epithelial tumor cell line T47D:A18/
PKCalpha cells is only observed in vivo or when cells are grown in
Matrigel but not in 2D tissue culture. This is not the case of C4-
HIR tumors shown here, which lost resistance to RU486 even in
3D cultures (Figure 8). Of course, not all the phenomena involved
in differential tumor sensitivity to antitumor agents can be
expected to be reproduced using the Matrigel culture system.
For C4-HIR tumors, it is likely that in vivo factors, such as
carcinoma-associated cells or paracrine signals are required to
maintain RU486 resistance. Thus, for C4-HIR tumors, a
complementary approach to the 3D culture system might be
suitable. For example, Pontiggia et al. used mixed epithelial-
stromal cultures (the LM05 cell line) to study estrogen respon-
siveness and tamoxifen resistance in vitro [47]. In their work, the
authors revealed that differences between certain tumor variants
could be ascribed to the particular stromal cell type of the mix.
These findings indicate that breast cancer progression is a very
complex phenomenon where alterations of special signaling
between particular cellular components could lead to a differential
tumor phenotype. This realization led to the recent development
of new drugs that instead of targeting the tumor cell, focus on its
microenvironment, summarized in references [25,30,31].
The PI3K/AKT signaling pathway has also been implicated in
altering breast cancer response to multiple therapies [1,10,11,14].
As described in this work, we showed that the inhibitory effect of
LY294002 on ERa levels is reduced when constitutively active
AKT1 was over-expressed in Scp2Akt cells (Figure 6). Consistent
with this result, high levels of AKT activity in myristoylated AKT1
MCF-7 cells confer resistance to the aromatase inhibitor letrozole
and to ICI182780 [48]. This resistance is not due to failure of the
endocrine agents to inhibit ERa activity; instead, it is character-
ized by an altered cell cycle and apoptotic response. Beeram et al.
[48] found that cotreatment with the mammalian target of
rapamycin (mTOR) inhibitor RAD-001 reverses the AKT-
mediated resistance and restores responsiveness to antiestrogens.
Together, these studies have implications for the design of
combination therapies that target alternative pathways and
appropriately adapted to particular characteristics of the tumor
progression.
In our system, besides its effect on the activation of AKT,
LY294002 caused a decrease in ERK activity (Figure 2),
suggesting a functional relationship between the two kinases.
Furthermore, inhibition of the two pathways by targeting MEK
and PI3K produced synergistic effects in inhibiting cell survival
(Figure 4), highlighting the interconnectivity of oncogenic signal
transduction circuits. The correlation between ERK and PI3K/
AKT signaling has been reported in breast cancer cells [29,49,50].
Furthermore, Weigelt et al. [28] state that during the acquisition of
resistance to targeted therapies, breast cancer cells are able to
rapidly adapt to different environments and signaling cues by
switching between alternative pathways, specifically PI3K/AKT
and RAS-MEK-ERK, that in turn regulate proliferation and cell
survival.
In this work, we also found a slight decrease in the protein levels
of AKT in response to LY294002 in C4-HI tumor cells (Figure 2)
but not in non-malignant Scp2 cells (Figure 6). This effect is in
accordance with a study that shows that treatment of aggressive
breast cancer cells with b galactoside binding protein (bGBP)
cytokine, another functional inhibitor of PI3K, induces apoptosis
through a reduction of AKT mRNA levels [50]. Furthermore, our
results indicate that LY294002 causes inhibition of tumor growth
(Figure 1) and increase in lumen formation in C4-HI cancer cells
through an intrinsic BAX/mitochondrial/activated caspase-9
apoptotic mechanism (Figure 5). This is in agreement with other
studies that show that suppression of AKT2 expression by shRNA)
in MCF-10A cells [51] or mouse mammary epithelial cells derived
from Akt12/2 mice [52] restored lumen formation, polarity and
Quantification of the percentage of apoptotic cells per cluster, of four independent experiments with ten clusters in each. Data corresponds to the
mean +/2 SEM. LY294002 induces cell death in C4-HI cells; **:p,0.01 vs. control. B. Confocal images showing higher BAX and activated caspase-9
staining, and lower Bcl-XL staining in C4-HI cells treated with 10 mM LY294002. Nuclei were stained red with propidium iodide. Scale bar: 30 mm.
doi:10.1371/journal.pone.0010786.g005
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PLoS ONE | www.plosone.org 10 May 2010 | Volume 5 | Issue 5 | e10786Figure 6. AKT regulates ERa protein expression. A.E R a levels determined by western blot are reduced in C4-HI tumors treated with PD98059
or LY294002 administrated as indicated in Figure 1. However, ERa levels are more variable between tumors and not regulated by either inhibitor in
C4-HD tumor samples. Top. Two representative samples of a total of six are shown in the gel. Bottom. Quantification of ERa relative to b-actin (used
as a loading control) levels. n=6 for each treatment; **:p,0.01 vs. control. B. A similar pattern of regulation of ERa protein is observed in primary
cells cultured on top of Matrigel and incubated for 48 hrs with 10 mM of either of the inhibitors. Top. Two representative samples of a total of six of
each group are shown in two independent gels. Bottom. Quantificaton of ERa relative to b-actin in each cell type. n=6 for each treatment; **p,0.01
vs. control. C. Representative confocal images showing ERa determined by immunofluoresence (green). Lower levels of the protein are seen in
PD98059-treated and in LY294002-treated C4-HI cells growing on Matrigel, whereas similar levels of ERa are seen in C4-HD treated and un-treated
cells. Nuclei were stained red with propidium iodide. Scale bar: 30 mm. D. Top. A representative sample for each treatment is shown in a western blot.
Scp2, a mouse mammary cell line, transfected with a constitutively active form of AKT1, myristoylated AKT1-D4-129 (Scp2Akt), displays in the same
gel AKT with a typical molecular weight of 59 kDa and the myristoylated deleted variant of AKT1 (p-myrAKT) with a molecular weight of 45 kDa. The
antibody used to detect total AKT recognizes only wild type AKT. E-cadherin was used as a loading control for Scp2 cells. Scp2Akt cells exhibit higher
levels of ERa than Scp2 cells transfected with the vector control (vc) or Scp2 control cells. In Scp2 and Scp2vc cells, but not in Scp2Akt cells, 2 and
5 mM LY294002 downregulate p-AKT and ERa levels, whereas total AKT levels remains invariable. Bottom. Quantification of ERa relative to E-cadherin
levels. n=4 for each treatment; a,b p,0.05 Scp2Akt vs. Scp2 and Scp2vc; *p,0.05 LY294002 vs. control.
doi:10.1371/journal.pone.0010786.g006
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presumptive luminal space in 3D Matrigel cultures.
We have previously shown that when C4-HI tumors are
exposed to estrogens they regress, and this phenomenon correlates
with a down regulation of ERa levels in the epithelial
compartment [53]. During tumor regression, there is a reduction
in proliferative and antiapoptotic molecules such as cyclin D1 and
Bcl-XL, respectively; and an increase in BAX release, leading to
the activation of the intrinsic apoptotic mechanism of caspase 9.
Finally, reduced ERa levels correlates with an increase in stromal
laminin-1 redistribution with a concomitant increase in integrin
a6, which contributes to enhance tumor regression by differen-
tiation [53]. In the light of the experiments shown here where
LY294002 causes ERa down regulation both in C4-HD and C4-
HI tumors (Figure 6) but tumor regression, by apoptosis and
differentiation, only in C4-HI tumors (Figure 1), we postulate that
AKT regulates C4-HI tumor growth, at least in part, by keeping
ERa levels. However, reduced levels of ERa are not sufficient to
Figure 7. C4-HD tumor cells are more sensitive to steroid receptor inhibitors. Apoptosis induced by inhibitors of ER (ICI182780) and PR
(ZK230211) is higher in C4-HD than C4-HI cells. Top: Phase contrast microscopy showing representative C4-HD (left) and C4-HI (right) cell clusters in
the presence of 1 mM ICI182780, 0.01 mM ZK230211 or vehicle as control. Confocal images from a fluorescence microscope of AO/EB staining show a
higher number of apoptotic cells (red cells) in C4-HD cultures treated with ICI182780 or ZK230211 than in C4-HD untreated cultures. C4-HI cultures
exhibit no change in cell death after endocrine treatments. Bottom. Quantification of the percentage of apoptotic C4-HD (left) and C4-HI (right) cells
per cluster, of four independent experiments with ten clusters in each. Data corresponds to the mean +/2 SEM. ***:p,0.001 vs. control. Scale bar:
30 mm.
doi:10.1371/journal.pone.0010786.g007
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reduced ERa levels, did not block tumor growth (Figure 1). The
finding of other mechanisms involved in tumor regression could
help us to increase the efficacy of tumor therapy to interfere with
tumor progression in this model.
Two observations from our studies led us to reconsider the
commonly held notion that as breast tumors progress from
hormone-dependent to hormone-independent, they become less
differentiated and more autonomous. The first observation
indicates that C4-HI tumors are more differentiated and display
more ductal-like structures than the original C4-HD tumors
(Figure 1). This difference is not due to the presence of MPA in the
C4-HD tumors because the administration of MPA to C4-HI
tumors does not interfere with its pattern of differentiation (not
shown). We suspect that in C4-HI tumors the PI3K/AKT and
steroid receptor pathways converge into a downstream signal that
maintains the observed differentiation pattern in C4-HI tumors. In
support of the convergence idea, a) we have previously reported
that C4-HI-derived cancer associated fibroblasts are able to induce
PR activation and cell proliferation of epithelial cells more
efficiently than C4-HD-derived cancer associated fibroblasts
[41]; b) we have previously determined that blocking steroid
receptors in vivo causes C4-HI tumor regression by differentiation
and cell death [53], and C4-HD tumors regress exclusively by cell
death with no particular spatial pattern [40,42]; and c) we show
here that treatment with LY294002 in vivo causes tumor
Figure 8. Loss of endocrine resistance in isolated C4-HIR tumor cells is not prevented by 3D Matrigel. Isolated C4-HI and C4-HIR tumor
cells are sensitive to cell death in response to RU486 when cultured on plastic, and the 3D Matrigel culture system is not sufficient to revert this
phenotype. A. C4-HI and C4-HIR tumors were transplanted in syngeneic mice and measured every 2 days (length and width). RU486 was inoculated
s.c. at a dose of 12 mg/kg/day once the tumors were 60 mm
2. C4-HI tumors (left) regress following treatment with antiprogestin, while C4-HIR
tumors (right) are unresponsive. B. Fluorescent confocal images of AO/EB staining show similar number of apoptotic cells (red cells) after 48 hrs of
treatment with 0.01 mM MPA and a higher number of apoptotic cells with 0.01 mM RU486 treatment. Right. Quantification of the percentage of
apoptotic C4-HI (upper) and C4-HIR (lower) cells per cluster, of three independent experiments with ten clusters in each. Data corresponds to the
mean +/2 SEM; ***:p,0.001 vs. control. Scale bar: 100 mm.
doi:10.1371/journal.pone.0010786.g008
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The 3D Matrigel system allowed us to localize apoptotic cells in
and around the central lumen of C4-HI cell clusters treated with
LY294002 (Figure 5), a phenomenon that correlates with tissue
differentiation. We will assess the convergence hypothesis further
in future studies.
The second observation indicates that C4-HI tumors are more
sensitive to PI3K/AKT and ERK regulation of ERa than C4-HD
tumors (Figure 6), and they can maintain such regulation when
they are grown on Matrigel. In such a culture system, we have
shown that C4-HI cells recover tissue polarity and lumen
formation (Figure 3). In previous studies, we have demonstrated
that SCg6 cells, a malignant mouse mammary cell line derived
from non-malignant Scp2 cells, become unresponsive to basement
membrane regulation of ERa expression [54]. These data indicate
that C4-HI tumors, although highly metastatic in lymph nodes
and lungs [55] are differentiated and are responsive to extracel-
lular matrix signals. These findings suggest that C4-HI tumors
could be more sensitive to the combination of PI3K, endocrine
and integrin modulators to interfere with their growth. Even the
progression from C4-HI to C4-HIR tumors could be impeded
with such combinatorial treatment. Future studies will be aimed to
test this hypothesis in animals.
In conclusion, based on the biomarkers of tumor progression
resulting from the studies in 3D cultures of the MPA breast cancer
model, it will be possible in the future to design and test multi-
targeted treatments involving a combination of selective inhibitors
of endocrine response, protein kinases and extracellular matrix
signals. Our study contributes to a relevant preclinical model
system that is suitable for testing the effectiveness of novel
therapies in targeting the whole tumor and not just the epithelial
component. Furthermore, the animal model that we used here has
the added advantage that it is composed of several tumor types
that were independently derived (the one presented in this study is
C4). In the future, we can determine if the processes that lead to
hormone independency and resistance are general and not a
unique event that occurs in this particular type of tumor.
Materials and Methods
Animals
Two-month-old virgin female BALB/c mice (IBYME Animal
Facility) were used. All animal procedures were approved by the
Ethical Committee from the Institute of Experimental Biology and
Medicine (IBYME): Dr. Enrique Segura, Dr. Ricardo Calandra,
Dr. Claudia Marro, Dr. Alberto Baldi and Dr Carlos Libertum.
Animal care and manipulation were in agreement with institu-
tional guidelines and the Guide for the Care and Use of
Laboratory Animals [56].
Tumors
Hormone-dependent C4-HD is a transplantable ductal mammary
tumor that is maintained by serial subcutaneous (s.c.) transplantations
into medroxyprogesterone acetate (MPA)-treated syngeneic BALB/c
female mice. Tumor growth is induced by a s.c. depot of MPA
(20 mg) in the contralateral flank of the mice [38]. A hormone-
independent tumor variant named C4-HI was derived from a C4-
HDtumorthatgrewinamousethathadnotbeentreatedwithMPA.
Both C4-HD and C4-HI tumor variants express ER and PR and
regress once silastic pellets of antiprogestin RU486 (6 mg/kg) were
s.c. implanted in the back of the animals [42].
A group of females carrying C4-HD or C4-HI tumors was
inoculated i.p. every other day for 12 days with saline solution
(control), PD98059 (3.6 mg/kg) or LY294002 (4 mg/kg). Doses
were adapted from the literature [57,58] and [44,45], respectively.
The tumor size was evaluated every 2 days using a Vernier caliper
to calculate tumor area (length and width) in mm
2. Treatments
with the inhibitors started once the tumors reached a size of
approximately 30 mm
2.
The generation of tumors with acquired resistance to anti-
progestin, C4-HIR, was performed by s.c. administration of
RU486 (12 mg/kg/day) to mice carrying C4-HI tumors
as described previously [7] and maintained by syngeneic
transplantation.
All experiments involving animals were repeated two or three
times using at least three mice per group each time, as indicated in
each figure.
Tumors smaller than 150 mm
2 growing in each determined
condition were excised after euthanasia of the animals and
immediately frozen at 280uC for western blots or formalin-fixed
for immunohistochemistry studies.
Paraffin sections were stained with hematoxylin-eosin. Sections
were analyzed using a Nikon Eclipse E800 Microscope and images
were taken with Nikon DS-U1 with ACT-2U (for Nikon) software.
Neither PD98059 nor LY294002 had a toxic effect after 12 days
of treatment, as determined by histological evaluation of kidney,
spleen and liver (data not shown).
Culture media and drugs
DMEM/F12 (Dulbecco’s modified Eagle’s medium: Ham’s
F12, 1:1, without phenol red, Sigma Chemical Company, St.
Louis, MO, USA), 100 U/ml penicillin and 100 mg/ml strepto-
mycin with 2% (for on top of Matrigel cultures) or 10% (for on
plastic cultures) fetal calf serum (FCS) (Bioser, Buenos Aires,
Argentina).
PD98059 and LY294002 were obtained from Calbiochem, La
Jolla,CA;RU486(mifepristone)fromSigmaChemicalCompany,St.
Louis, MO. MPA was kindly provided from Craveri Laboratorios,
Buenos Aires, Argentina; ZK230211 was kindly provided by Bayer
Schering Pharma AG, Berlin; and ICI182780 (fulvestrant) was kindly
provided by AstraZeneca London, United Kingdom.
Mouse mammary epithelial cells
Primary mammary epithelial organoids were prepared by a
procedure described previously [43] using the 4th inguinal
mammary glands from nulliparous two-months virgin BALB/c
mice. Epithelial organoids were resuspended in 2% FCS DMEM/
F12 growth medium on top of Matrigel.
Scp2 cell line
A functionally normal mouse mammary epithelial cell line, Scp2
[59] was kindly provided by Dr. Mina Bissell (LBNL, Berkeley,
CA) and maintained in 2% FCS DMEM/F12 on tissue culture
plastic. Scp2 cells were transfected using Lipofectamine 2000
(Invitrogen Corporation) with a pWZL plasmid containing
myristoylated AKT1, kindly provided by Dr. Richard Roth
(Stanford, CA). This AKT1 variant lacks amino acids 4 to 129
(D4–129) and bears a myristoylation signal that causes its
constitutive activation [60]. Scp2 transfected with myristoylated
AKT1 were named Scp2Akt. Scp2 cells transfected with empty
pWZL plasmid were named Scp2vc. The cells were lysed using M-
PER mammalian protein extraction reagent (Pierce, Rockford, IL)
48 hrs after transfection, and prepared for western blotting.
Tumor primary cultures
Epithelial cell clusters were separated by differential sedimen-
tation from C4-HD, C4-HI or C4-HIR tumors as indicated in
3D Assay and Tumor Sensitivity
PLoS ONE | www.plosone.org 14 May 2010 | Volume 5 | Issue 5 | e10786[38] and plated with 2% or 10% FCS, as indicated above. The
cells were maintained with the indicated medium for 48 hrs.
Then, the medium was replaced by 0% FCS DMEM/F12 for
another 48 hrs. During this period, different drugs were added to
the 0% FCS medium, such as 5, 10 or 20 mM PD98059; 5, 10 or
20 mM LY294002, 1 mM ICI182780, 0.01 mM ZK230211,
0.01 mM MPA, and 0.01 mM RU486, or the vehicle (DMSO) as
a control.
Cultures in 3D
For 3D cultures, approximately 10
5 epithelial cells/ml were
seeded on top a reconstituted basement membrane gel (MatrigelH,
phenol red free, growth factor reduced Matrix, BD Biosciences-
Discovery Labware) according to [21,43]. The Matrigel coverage
was prepared according to the manufacturer’s instructions by
using 70 ml of Matrigel to cover an 8-well Lab Tek Permanox
chamber slide (Nalge Nunc International). For western blot assays
140 ml of Matrigel were used to cover each well of a 12-well plate.
After isolation from the tumor, epithelial cells were seeded on top
of the Matrigel, in 2% FCS-DMEM/F12 medium. After 48 hrs,
the medium was removed, and all the experiments and treatments
were carried out in serum free DMEM/F12 medium. The cells
were incubated for other 48 hrs in the presence of PD98059,
LY294002, ICI182780, ZK230211, MPA, or RU486, as indicat-
ed. The volume of Matrigel was used to calculate the final
concentration of the compounds. At the end of the treatment, the
medium was removed, and the gel containing the cells was gently
washed twice with PBS.
Apoptosis
Apoptosis in the tumor tissue was morphologically determined
in paraffin sections previously stained with hematoxylin-eosin. The
percentage of apoptosis was calculated as the number of cells
undergoing apoptosis over the total number of cells in ten high-
power fields.
Cell apoptosis in culture was evaluated by staining the cells on
top of the Matrigel for 10 seconds with acridine orange (AO) and
ethidium bromide (EB) for discrimination of live from dead cells
on the basis of membrane integrity [61,62]. The final concentra-
tion of dye mix was 4 mg/ml AO and 4 mg/ml EB in PBS. AO/EB
staining was used to visualize nuclear changes and apoptotic body
formation. Live cells fluoresce green (with acridine orange) and
dead cells fluoresce orange/red (with ethidium bromide that
intercalates with double-stranded DNA). Images were taken using
a fluorescence confocal Nikon C1 microscope equipped with
excitation and emission filters for acridine orange (488 nm and
520 nm, respectively) and for ethidium bromide (544 nm and 570-
LP nm). Percentage of apoptotic cells was calculated as the
number of red cells over the total number of cells in each cluster in
ten clusters.
Cell proliferation
A
3H-Thymidine uptake assay was performed as previously
described [63]. Briefly, in a Corning 96-well microplate, 0.1 ml/
well of a cell suspension was seeded directly (with no Matrigel
coverage) at a concentration of 10
5 cells/ml. After attachment
(48 hrs), the cells were incubated for another 48 hrs with the
experimental solutions to be tested. The cells were incubated with
0.4 mCi of
3H-thymidine (specific activity: 20 Ci/mmol) for the
last 18 hrs, trypsinized and harvested in a cell harvester. Filters
were counted in a liquid scintillation counter. Assays were
performed in octuplicates and the mean and standard deviation
were calculated for each solution tested.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were reacted with the
phosphorylated Ser473 AKT (p-AKT) antibody (sc-33437, from
Santa Cruz Biotechnology, CA) using the avidin/biotin peroxidase
complex technique (Vectastain Elite ABC kit; Vector Laboratories,
Burlingame, CA). The reactions were developed with 3-39diami-
nobenzidine (DAB) as described [42]. Primary antibody was used
at 1:100 dilution and incubated overnight at 4uC. After
immunohistochemistry, the specimens were lightly counterstained
with 10% hematoxylin, dehydrated, and mounted.
Immunofluorescence
Cell clusters seeded on top of Matrigel in chamber slides were
washed and fixed in 10% formalin for 20 minutes at room
temperature. Fixed clusters were treated with primary antibodies
to integrin a6 (555734, from BD Pharmigen, San Diego, CA);
MUC-1 (62687) and activated caspase-9 (52298) from Abcam,
Cambridge, UK; ZO-1 (61–7300) from Zymed Laboratories,
San Francisco, CA; BAX (sc-526), Bcl-XL (sc-634) and ERa (sc-
542) from Santa Cruz Biotechnology, CA. The antibodies were
dissolved in blocking buffer at appropriate dilution and
incubated overnight at 4uC. The corresponding secondary
FITC-conjugated antibodies (Vector Laboratories Burlingame,
CA) were dissolved at 1:100 dilution and incubated for 1 hr at
room temperature. The nuclei were stained with propidium
iodide. Slides were mounted with Vectashield (Vector Labora-
tories, Burlingame, CA) and analyzed under a Nikon C1
Confocal Microscope using the EZ-C1 2.20 software and a
PlanApo 40X/0.95 objective.
Protein extraction and western blots
Tumors were homogenized and processed to obtain total
fractions for western blot as described previously [41]. To
prepare cell culture total extracts, the cells were lysed using M-
PER mammalian protein extraction reagent (Pierce, Rockford,
IL). For protein extraction of primary cells grown on top of
Matrigel, the cell clusters were previously removed from the gel,
with a gently digestion of the gel using Matrisperse BD Cell
Recovery Solution (BD Biosciences - Discovery Labware)
according to manufacturer’s instructions. Once the clusters were
recovered, cell lysis was performed using M-PER reagent.
Similar amounts of protein extracts as determined by Lowry
were loaded into each lane. Western blot were performed and
the membranes were incubated with antibodies specific for ERa
(sc-542), ERK (sc-94) and p-ERK (sc-7383) all purchased from
Santa Cruz Biotechnology; total AKT (610837) and E-cadherin
(610181) from BD Transduction Laboratories; phosphorylated
Ser473 AKT (p-AKT) (9271) from Cell Signaling Tech,
Danvers, MA; b-actin (clone ACTN05) from Neomarkers, Lab
Vision Corp. All primary antibodies were incubated overnight at
4uC at a final concentration that was suggested by manufactur-
er’s instructions.
Statistical analysis
Western blot band intensity and cell staining were quantified
using the Image J software. ANOVA and the Tukey multiple post t
test were used to study the differences of means of multiple
samples; the Student’s t test was used to compare the means of two
different groups. Tumor growth curves were studied using
regression analysis, and the slopes were compared using ANOVA
followed by parallelism analysis. Data analysis was performed
using the Graph Prism 4.0 software.
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